![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00111956 |
Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
Condition | Intervention |
Metabolic Syndrome X |
Drug: Etanercept |
MedlinePlus related topics: | Metabolic Syndrome |
ChemIDplus related topics: | Etanercept Tumor Necrosis Factors |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Estimated Enrollment: | 56 |
Study Start Date: | April 2004 |
Study Completion Date: | May 2005 |
![]() |
Show Detailed Description |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | TNF-alpha |
First Received: | May 26, 2005 |
Last Updated: | December 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00111956 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
![]() |